EPHA has joined the call led by the European Alliance for Responsible R&D and Affordable Medicines to urge EU Ministers to ensur the Regulation for a reinforced EMA role leads to enhanced clinical trial transparency and upholds good governance. We call on Me States and the EMA to make the most of the Clinical Trial Regulation and ensure that any Clinical Trials Information System (CTIS) monitoring data capturing stakeholders' performance is made publicly available in full and on an ongoing basis through the public C interface. This will facilitate public accountability and translate into greater compliance. We also call on the EU institutions to ensure information on clinical trials is communicated in a timely, user-friendly, and comprehensive manner during public health crises.



Transparency of clinical trials

Patients, consumers, civil society